What's Possible? Generative AI and Health Care

Generative AI is likely to transform the pharmaceutical industry with its capabilities for content creation and personalization, and ability to mine insights from large quantities of unstructured data.
In the second in a series explaining what’s possible with GenAI, BCG’s Chris Meier explores the promise of greater efficiency and faster innovation in healthcare and drug development.*
Welcome to the official RUclips channel for The Boston Consulting Group. Since 1963, BCG’s experts have been helping businesses, governments, and non-profit organizations build lasting advantage. As a leading management consulting firm, BCG empowers clients to make the changes needed to seize the competitive advantage and win. The independent spirit handed down from Bruce Henderson, BCG's founder-always challenging the status quo-has given the firm the courage to look beyond the obvious in pursuit of lasting solutions for our clients.
Subscribe to BCG’s RUclips channel: goo.gl/hsFsVT
Visit us at www.bcg.com

[@TheBostonConsultingGroup]

This text was drafted by ChatGPT, checked by BCG editors. Part one of this series, on GenAI and marketing, can be found here: ruclips.net/video/PVVUPUJeezo/видео.html